Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer

International Journal of Gynecology and Obstetrics

Volumn 108, Issue 2, 2010, Pages 123-127

  Schorge, John O ^a   Wingo, Shana N ^b   Bhore, Rafia ^c   Heffernan, Thomas P ^b   Lea, Jayanthi S ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d CAROLINAS MEDICAL CENTER   (United States)

Author keywords

Recurrent ovarian cancer; Secondary cytoreductive surgery

Indexed keywords

PLATINUM;

ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOREDUCTIVE SURGERY; DRUG SENSITIVITY; FEMALE; HUMAN; MINIMAL RESIDUAL DISEASE; OVARY CANCER; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECURRENT CANCER; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 73749084107     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijgo.2009.08.034     Document Type: Article

References (20)

1. Schorge J.O. Epithelial Ovarian Cancer. In: Schorge J.O., Schaffer J.I., Holverson L.M., Hoffman B.L., Bradshaw K.D., and Cunningham F.G. (Eds). Williams' Gynecology. 1st edn. (2008), McGraw-Hill, New York 716
2. Covens A.L. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 78 3 Pt 1 (2000) 269-274
3. Aletti G.D., Dowdy S.C., Gostout B.S., Jones M.B., Stanhope C.R., Wilson T.O., et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 107 1 (2006) 77-85
4. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20 5 (2002) 1248-1259
5. Chi D.S., Eisenhauer E.L., Lang J., Huh J., Haddad L., Abu-Rustum N.R., et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. Gynecol Oncol 103 2 (2006) 559-564
6. Wimberger P., Lehmann N., Kimmig R., Burges A., Meier W., Du Bois A., et al. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 106 1 (2007) 69-74
7. Bristow R.E., Peiretti M., Gerardi M., Zanagnolo V., Ueda S., Diaz-Montes T., et al. Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome. Gynecol Oncol 114 2 (2009) 173-177
8. Bristow R.E., Puri I., and Chi D.S. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 112 1 (2009) 265-274
9. Chi D.S., McCaughty K., Diaz J.P., Huh J., Schwabenbauer S., Hummer A.J., et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106 9 (2006) 1933-1939
10. Fotiou S., Aliki T., Petros Z., Ioanna S., Konstantinos V., Vasiliki M., et al. Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer. Gynecol Oncol 114 2 (2009) 178-182
11. Salani R., Santillan A., Zahurak M.L., Giuntoli II R.L., Gardner G.J., Armstrong D.K., et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer 109 4 (2007) 685-691
12. Klein J.P., and Moeschberger M.L. Survival analysis: techniques for censored and truncated data (2003), Springer-Verlag, London
13. Eisenkop S.M., Friedman R.L., and Spirtos N.M. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88 1 (2000) 144-153
14. Zang R.Y., Li Z.T., Tang J., Cheng X., Cai S.M., Zhang Z.Y., et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?. Cancer 100 6 (2004) 1152-1161
15. Benedetti Panici P., De Vivo A., Bellati F., Manci N., Perniola G., Basile S., et al. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol 14 3 (2007) 1136-1142
16. Tay E.H., Grant P.T., Gebski V., and Hacker N.F. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol 99 6 (2002) 1008-1013
17. Gronlund B., Lundvall L., Christensen I.J., Knudsen J.B., and Hogdall C. Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum. Eur J Surg Oncol 31 1 (2005) 67-73
18. Tebes S.J., Sayer R.A., Palmer J.M., Tebes C.C., Martino M.A., and Hoffman M.S. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 106 3 (2007) 482-487
19. Scarabelli C., Gallo A., and Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 83 3 (2001) 504-512
20. Onda T., Yoshikawa H., Yasugi T., Yamada M., Matsumoto K., and Taketani Y. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br J Cancer 92 6 (2005) 1026-1032